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Volume 56, Number 6 Abstracts 1815Atlantic Intersocietal Conference (TASC) II guidelines. The aim of this study
was to determine the proportion of patients with chronic critical limb ischemia
(CLI) who failed to adhere to current guidelines of medical therapy and to
quantify the effect of suboptimal medical management on amputation-free
survival (AFS).
Methods: The patient cohort was identified from a prospectively
maintained database of consecutive patients presenting with CLI to the
vascular surgery service at one hospital. The primary outcome variable was
AFS. The effects of baseline demographics, comorbid medical conditions,
ambulatory status, optimal medical management, and Rutherford classifica-
tion were assessed. Optimal medical management was defined as adherence
to TASC II recommendations for the management of atherosclerotic risk
factors. Significant univariate predictors (P .10) of AFS were entered into
a multivariate Cox proportional hazards model.
Results: From August 1, 2010, through January 1, 2012, 98 patients
(mean [standard deviation] age, 59.9 10.1 years; 58 men and 40 women)
were evaluated with rest pain (n  38) or tissue loss (n  60). The mean
follow-up for the cohort was 333.3  196.1 days. Optimal medical man-
agement was identified in 32% of patients at initial presentation, including
compliance rates of 63% for statin use, 71% on antiplatelet therapy, 51% for
angiotensin-converting enzyme inhibitor use, and 49% for -blocker use.
Significant univariate predictors of major amputation or death included
nonambulatory status (hazard ratio [HR] 2.17; 95% confidence interval
[CI], 1.68-2.81; P  .01), un-revascularized patients (HR, 2.77; 95% CI,
1.32-5.85; P  .01), a history of tobacco abuse (HR, 1.49; 95% CI,
0.57-3.86; P  .09), a history of end-stage-renal disease (HR, 7.97; 95%
CI, 3.10-20.52; P .01), suboptimal medical management (HR, 4.25; 95%
CI, 1.28-14.07; P  .02), and an absence of antiplatelet agents (HR, 1.94;
95% CI, 0.92-4.11; P  .08). Independent predictors of major amputation
or death included initial nonambulatory status (HR, 2.43; 95% CI, 1.03-
2.05; P .01), un-revascularized status (HR, 2.43; 95% CI, 1.76-3.34; P
.01), and suboptimal medical management at presentation (HR, 8.54; 95%
CI, 2.05-35.65; P  .01).
Conclusions: Despite guidelines advocating the optimization of ath-
erosclerotic risk factors in peripheral arterial disease, less than one-third of
patients with CLI present with their risk factors appropriately managed.
Patients who are suboptimally medically managed have greater than a
fourfold risk of major amputation or death, or both. Of the risk factors
affecting amputation-free survival, medical therapy optimization is the vari-
able that can be most significantly improved by vascular surgeons and the
medical community. Population-based efforts to improve outcomes in CLI
require attention to improving the medical management.
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Introduction: Beyond traditional indications, subclavian revascular-
ization is increasingly performed to allow for aortic arch debranching in the
setting of thoracic endovascular aortic repair (TEVAR). Endovascular ap-
proaches have also emerged as a therapeutic option for subclavian artery
disease, perhaps altering the patient population undergoing open proce-
dures. We leveraged prospectively collected National Surgical Quality Im-
provement Program (NSQIP) data to delineate evolving stroke and mortal-
ity rates after carotid-subclavian bypass (CSB) and subclavian-carotid
transposition (SCT) in this dynamic context.
Methods: The American College of Surgeons NSQIP database (2005-
2010) was used to examine adult patients who underwent CSB or SCT.
Patients admitted for emergency procedures were excluded. Factors associ-
ated with the primary outcome (30-day postoperative stroke or death) were
defined using univariable and multivariable analyses.
Results: Of 877 patients who met inclusion and exclusion criteria, 738
underwent CSB, 139 underwent SCT, and 88 (10.0%) also underwent TE-
VAR. CSB comprised 41% of subclavian revascularizations associated with
TEVAR and 89% of isolated subclavian revascularizations. The CSB and SCT
group had similar baseline age (65.0 vs 63.3 years, P  .67), race (Caucasian,
83.8% vs 79.4%, P .21), and prevalence of comorbid conditions. There were
a greater proportion of TEVARs performed in the SCT group (37.4% vs 4.9%,
P .01). The groups were otherwise similar in demographic characteristics and
prevalence of comorbid conditions. Overall stroke, mortality, and combined
cerebrovascular accident (CVA)/death (D) rateswere 3.5% (n31), 3.3% (n
29), and 5.8% (n  51), respectively. Surgical approach did not affect the
CVA/D rate (odds ratio [OR], 1.51; 95% confidence interval [CI], 0.71-3.19;
P .28); however, increasing age (adjustedOR, 1.06; 95%CI, 1.03-1.10; P
.01), congestive heart failure (OR, 3.49; 95% CI, 1.04-11.64; P  .04), and
American Society of Anesthesiologists class3 (OR, 2.06; 95% CI, 1.11-3.83;
P  .02) were significantly associated with CVA/D in the overall group. The
CVA/D rate was 10.2% (n  9) for revascularization in conjunction with
TEVAR and 5.3% (n  42) for isolated reconstruction (P  .06). Without
excluding emergency cases, the TEVAR cohort’s CVA/D rate was 14.7%. For
patientsundergoingTEVAR,no factorswere significantly associatedwithCVA/D,
m
tncluding surgical approach (SCTvsCSB;OR,0.52; 95%CI, 0.13, 2.08;P .35).
or patients undergoing isolated revascularization, increasing age (OR, 1.06; 95%
I, 1.03-1.10;P .01) andnonindependent functional status (OR,3.49; 95%CI,
.41-8.68; P .01) were significantly associated with CVA/D.
Conclusions: Despite improvements in surgical, anesthetic, and
ritical care technology, open cervical reconstruction of the subclavian
rtery for occlusive disease carries a persistent combined CVA/D rate
5% in this contemporary work. With TEVAR, this rate is as high as
0.2%. There was no significant difference in CVA/D by surgical ap-
roach after adjustment for other factors. CVA/D continues to compli-
ate contemporary CSB and SCT, especially among elderly and noninde-
endent patient subsets.
able. Outcome, stratified by TEVAR and surgical approach
ariable No. CVA/D Death CVA
No. (%) No. (%) No. (%)
ll patients 877 51 (5.8) 29 (3.3) 31 (3.5)
EVAR
Overall 88 9 (10.2) 6 (6.8) 5 (5.7)
CSB 36 5 (13.9) 3 (8.3) 3 (8.3)
SCT 52 4 (7.7) 3 (5.8) 2 (3.9)
on-TEVAR
Overall 789 42 (5.3) 23 (2.9) 26 (3.3)
CSB 702 36 (5.1) 20 (2.9) 22 (3.1)
SCT 87 6 (6.9) 3 (3.5) 4 (4.6)
mproved Procedural, Hemodynamic, and Late Clinical Outcomes
sing Intravascular Ultrasound Anatomic Guidance During Carotid
rtery Stent-Angioplasty
egan I. Carroll, Patrick McNair, Martin R. Back, Neil Moudgill, Murray
. Shames, Karl A. Illig, Brad L. Johnson, Paul A. Armstrong. University of
outh Florida, Tampa, Fla
Introduction: This study evaluates carotid artery stenting (CAS) with
nd without intravascular ultrasound (IVUS) interrogation assessing the
egion of stent deployment and angioplasty.
Methods: A retrospective review of a carotid stent registry from 2003
o 2012 identified 412 CAS procedures (399 patients) to treat de novo
therosclerosis or recurrent stenosis of the carotid bulb and internal carotid
rtery. Imaging with IVUS was performed before and after stent-angio-
lasty. Residual stent stenosis on angiography or IVUS was treated with
dditional percutaneous transluminal angioplasty (PTA). Surveillance du-
lex ultrasound imaging was performed at 30 days, followed by 6-month
ntervals. Outcome measures included procedure time, final balloon diam-
ter for PTA, contrast volume, hemodynamic parameters on duplex, cardiac
vents, neurologic outcome, and mortality.
Results: CAS was performed using digital C-arm angiography alone
AA) in 167 or in conjunction with IVUS (AI) in 241; 314 patients (77%)
ere asymptomatic. Using AA or AI, accurate single carotid stent deploy-
ent was achieved. Mean procedure times were similar between AA and AI
roups (63.0 vs 63.4 min, P  .87). Compared with AA, AI altered
rocedural conduct by using lower contrast volumes (mean 50 mL; range
-120 mL) compared with AA (mean, 90 mL; range, 40-170 mL) due to
ewer angiogram runs for stent sizing and verification of adequate stent
eployment. AI directed use of larger-diameter balloons, ranging in size
rom 5.5 to 7 mm (median 6 mm), for final stent PTA based on assessment
f normal luminal diameter, whereas AA balloons were 4.5 to 6 mm
median, 5 mm; P  .0001). AI also detected more residual stent abnor-
alities (n 24 [10%]) vs CAS using AA (n 3 [2%], P .002). The early
30-day) duplex scan showed 24 of 27 stents (89%) receiving adjunctive
TA for residual stent stenosis demonstrated 50% DR. Early neurologic
vent rates were low, and there was no different between groups (AA 1.2% vs
I 1.2%). Duplex at 30-days and last surveillance interval is recorded in the
able. Mean follow-up was 54 months (range, 6-120 months). Duplex at
0-days showed DR 50% to 75% was more likely in the AA group (P .02).
t the last duplex, DR50% were recorded for 26 AA (16%) and 9 AI CAS
4%; P  .0001). Six CAS sites (5 AA, 1 AI, P  .0001) developed 75%
symptomatic restenosis and underwent secondary percutaneous interven-
ion with PTA, with one AA stent later developing an asymptomatic throm-
osis. Each group had one late neurologic event, one stroke (AA), and one
ransient ischemic attack (AI; 0.6%, 0.4% respectively). One early cardiac
eath was recorded in an AI patient.
Conclusions: IVUS guidance allows operators to accurately define
isease distribution, vessel size, and target stent landing zones without
dding independent risk or increasing procedural time. IVUS affords a
easure of quality control that directs optimal stent and balloon selec-
ion. Adjunctive use of IVUS can improve early and late carotid stent
